Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 32, 2002 - Issue 10
208
Views
53
CrossRef citations to date
0
Altmetric
Research Article

Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices

, , , , , , & show all
Pages 849-862 | Published online: 22 Sep 2008

References

  • ACHEAMPONG, A. A., CHIEN, D.-S., LAM, S., VEKICH, S., BREAU, A., USANSKY, J., HARCOURT, D., MUNK, S. A., NGUYEN, H., GARST, M. and TANG-Liu, D., 1996, Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase. Xenobiotica, 26, 1035–1055.
  • ANDERSSON, T. B., SJOBERG, H., HOFFMANN, K.-J., BOOBIS, A. R., WATTS, P., EDWARDS, R. J., LAKE, B. G., PRICE, R. J., RENWICK, A. B., GômEz-LEcHôN, M. J., CASTELL, J. V., INGELMAN-SUNDBERG, M., HIDESTRAND, M., GOLDFARB, P. S., LEWIS, D. F. V., CORCOS, L., GUILLOUZO, A., TAAVITSAINEN, P. and PELKONEN, O., 2001, An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. Drug Metabolism and Disposition, 29, 712–720.
  • BEAMAND, J. A., PRICE, R. J., CUNNINGHAME, M. E. and LAKE, B. G., 1993, Culture of precision-cut liver slices: effect of some peroxisome proliferators. Food and Chemical Toxicology, 31, 137–147.
  • BEER, B., IENI, J. R., Wu, W.-H., CLODY, D., AMORUSI, P., ROSE, J., MANT, T., GAUDREAULT, J., CATO, A. and STERN, W., 1994, A placebo-controlled evaluation of single, escalating doses of CL-284,846, a non-benzodiazepine hypnotic. Journal of Clinical Pharmacology, 34, 335–344.
  • CHAUDHARY, I., DEMALO, W. and KANTROWITZ, J., 1994, Species comparison of in vitro and in vivo metabolism of CL- 284,846, a non- benzo diazepine sedative/hypnotic agent. Pharmaceutical Research, 11, S391.
  • CLARKE, S. E., 1998, In vitro assessment of human cytochrome P450. Xenobiotica, 28, 1167-1202. CORNISH-BOWDEN, A., 1974, A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochemical Journal, 137, 143–144.
  • DIXON, M., 1953, The determination of enzyme inhibitor constants. Biochemical Journal, 55, 170–171.
  • HOUSTON, J. B. and CARLILE, D. J., 1997, Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metabolism Reviews, 29, 891–922.
  • HOUSTON, J. B. and KENWORTHY, K. E., 2000, In vitro—in vivo scaling of CYP kinetic data not consistent with the classical Michaelis—Menten model. Drug Metabolism and Disposition, 28, 246–254.
  • KAWASHIMA, K., Hosoi, K., NARUKE, T., SHIBA, T., KITAMURA, M. and WATABE, T., 1999, Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. Drug Metabolism and Disposition, 27, 422–428.
  • LAKE, B. G., 1987, Preparation and characterisation of microsomal fractions for studies of xenobiotic metabolism. In K. Snell and B. Mullock (eds), Biochemical Toxicology: A Practical Approach (Oxford: IRL Press), pp. 183–215.
  • LAKE, B. G., BALL, S. E., KAD, J., RENWICK, A. B., PRICE, R. J. and SCATINA, J. A., 2002, Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica, 32, 835–847.
  • LIN, J. H. and Lu, A. Y. H., 1998, Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Pharmacokinetics, 35, 361–390.
  • LOWRY, O. H., ROSEBROUGH, N. J., FAR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
  • PELKONEN, O., MYLLYNEN, P., TAAVITSAINEN, P., BOOBIS, A. R., WATTS, P., LAKE, B. G., PRICE, R. J., RENWICK, A. B., GOmEz-LEcoON, M.-J., CASTELL, J. V., INGELMAN-SUNDBERG, M., HIDESTRAND, M., GUILLOUZO, A., CORCOS, L., GOLDFARB, P. S. and LEWIS, D. F. V., 2001, Carbamazepine: a 'blind' assessment of CYP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica, 31, 321–343.
  • RASHIDI, M. R., SMITH, J. A., CLARKE, S. E. and BEEDHAM, C., 1995, Inhibition of human and guinea-pig liver aldehyde oxidases in-vitro. Journal of Pharmacy and Pharmacology, 47, 1090.
  • RENWICK, A. B., MISTRY, H., BALL, S. E., WALTERS, D. G., KAO, J. and LAKE, B. G., 1998, Metabolism of zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica, 28, 337–348.
  • ROBERTSON, I. G. C. and BLAND, T. J., 1993, Inhibition by SKF-525A of the aldehyde oxidase-mediated metabolism of the experimental antitumour agent acridine carboxamide. Biochemical Pharmacology, 45, 2159–2162.
  • RODRIGUES, A. D., FERRERO, J. L., AMANN, M. T., ROTERT, G. A., CEPA, S. P., SURBER, B. W., MACHINIST, J. M., TICH, N. R. SULLIVAN, J. P., GARVEY, D. S. FITZGERALD, M. and ARNERIC, S. P., 1994, The in vitro hepatic metabolism of ABT-418, a cholinergic channel activator, in rats, dogs, Cynomolgus monkeys, and humans. Drug Metabolism and Disposition, 22, 788–798.
  • ROSEN, A. S., FOURNIE, P., DARWISH, M., DANJOU, P. and TROY, S. M., 1999, Zaleplon pharmacokinetics and absolute bioavailability. Biopharmaceutics and Drug Disposition, 20, 171–175.
  • SMITH, S. R. and KENDALL, M. J., 1988, Ranitidine versus cimetidine: a comparison of their potential to cause clinically important drug interactions. Clinical Pharmacokinetics, 15, 44–56.
  • SOMOGYI, A. and MUIRHEAD, M., 1987, Pharmacokinetic interactions of cimetidine 1987. Clinical Pharmacokinetics, 12, 321–366.
  • STEENSMA, A., BEAMAND, J. A., WALTERS, D. G., PRICE, R. J. and LAKE, B. G., 1994, Metabolism of coumarin and 7-ethoxycoumarin by rat, guinea pig, Cynomolgus monkey and human precision-cut liver slices. Xenobiotica, 24, 893–907.
  • TANAKA, E., 1998, Clinically important pharmacokinetic drug—drug interactions: role of cytochrome P450 enzymes. Journal of Clinical Pharmacy and Therapeutics, 23, 403–416.
  • UENG, Y.-F., KUWABARA, T., CHUN, Y.-J. and GUENGERICH, F. P., 1997, Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry, 36, 370–381.
  • WORBOYS, P. D., BRADBURY, A. and HOUSTON, J. B., 1997, Kinetics of drug metabolism in rat liver slices. III. Relationship between metabolic clearance and slice uptake rate. Drug Metabolism and Disposition, 25, 460–467.
  • WRIGHTON, S. A. and RING, B. J., 1994, Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine. Pharmaceutical Research, 11, 921–924.
  • WU, W. H., Dicioccio, A. T., DEMAIO, W., AMORUSI, P., TONELLI, A. P. and MAYER, P. R., 1996, Mass balance and pharmacokinetics of zaleplon, a non-benzodiazepine sedative/hypnotic, in man. Pharmaceutical Research, 13, S487.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.